Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline
resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III
study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable
pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with
neoadjuvant chemoradiation therapy.